More specifically, it was then also shown that treatment with the monoclonal antibody 4C5 blocked zymogens MMP2 and MMP9 processing to their active forms which concurred with disruption of their interactions with eHsp90 and inhibition of breast cancer cell metastasis to the lung (Stellas et al., 2010). The gene discussed is MMP2; the disease is breast carcinoma.